- Screen cyanobacterial strains for beneficial properties towards obesity and obesity-related co-morbidities
- Isolate and elucidate the chemical structures of novel compounds responsible for observed bioactivities
- Characterize the biological properties of novel compounds: focus on the understanding of the underlying molecular mechanism and deciphering of molecular targets
The WP1 will comprise the biomass production from cyanobacterial strains from the Blue
Biotechnology and Ecotoxicology Culture Collection (LEGE CC) of CIIMAR, and the chemical work related to the (i) production of (sub)fractions and the (ii) elucidation of chemical structure. Produced biomass will be extracted and fractionated, and forwarded for biological activity testing in WP2.
The specific objective of WP2 is to elucidate the effects of cyanobacterial derived fractions on obesity-related metabolic diseases (obesity, hyperlipidemia, fatty liver disease, diabetes). Analysis of biological activity is a central part of the project and will provide feedback for production of (sub)fractions (WP1) leading to isolated compounds.
The main objectives are to elucidate the target actions of those novel compounds and potential side effects. We will provide an integrated platform for the rapid characterization of bioactive compounds through their targeting profiles by chemical proteomics, and for elucidating the molecular networks responsible for specific phenotypes by quantitative proteomics. Proof of concept integrating obtained in vitro results will be done in the obesity mouse in vivo.
The overall aims are to set-up a suitable management structure of the project that will ensure the overall management, conflict resolution and quality assurance.
A further goal is to disseminate the project aims and results to different stakeholder groups, in particular the scientific community, potential industrial collaboration partners and the general public.
CIIMAR – Interdisciplinary Centre of Marine and Environmental Research – is a research and advanced training institution hosted by the University of Porto. Its mission is to develop exceptional-quality research, promote technological development and innovation and support public policies in the area of Marine and Environmental Sciences.
Linköping University, LiU, conducts world-leading, boundary-crossing research in fields that include natural science, biomedicine, materials science, and IT. In the same spirit, the university offers many innovative educational programmes, frequently with a clear professional focus and leading to qualification as, for example, doctors, teachers, economists and engineers.
As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus, lung diseases and allergy. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle.
ArcticMass is based in Reykjavðk, Iceland. The employees of ArcticMass are highly experienced in bioanalysis and most of them are former members of the bioanalytical laboratory of deCODE genetics.
ArcticMass offers high quality bioanalytical services for the pharmaceutical industry, using analytical techniques like LC-MS/MS, UPLC-MS/MS, LC-Q-TOF, HPLC-FL and HPLC-UV. ArcticMass has a strong relationship with a high quality in vivo laboratory.
The Faculty of Pharmaceutical Sciences is an educational and research institution of international standing, which has close ties with Icelandic industry and society. The faculty is a vibrant and highly valued research and teaching unit; in fact it is one of the most productive of the University's Faculties.
CIIMAR | Interdisciplinary Centre of Marine and Environmental Research of the University of Porto
Edifício do Terminal de Cruzeiros do Porto de Leixões
Avenida General Norton de Matos, S/N
4450-208 Matosinhos | Portugal | Tel. (+351) 223 401 840
This work is financed by national funds through FCT (Portugal), BMBG (Germany), Rannis (Iceland and Formas (Sweden), within the framework of the European ERA-NET Marine Biotechnology project CYANOBESITY.